PE20212178A1 - Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria - Google Patents

Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria

Info

Publication number
PE20212178A1
PE20212178A1 PE2021001647A PE2021001647A PE20212178A1 PE 20212178 A1 PE20212178 A1 PE 20212178A1 PE 2021001647 A PE2021001647 A PE 2021001647A PE 2021001647 A PE2021001647 A PE 2021001647A PE 20212178 A1 PE20212178 A1 PE 20212178A1
Authority
PE
Peru
Prior art keywords
hexahydro
pyrazino
treatment
autoimmune disease
pyrazine compounds
Prior art date
Application number
PE2021001647A
Other languages
English (en)
Spanish (es)
Inventor
Wei Zhu
Zhiwe Zhang
Zhisen Zhang
Hong Shen
Yongfu Liu
Yafei Liu
Haixia Liu
Buyu Kou
Fabian Dey
Lue Dai
Linuo Zhu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20212178A1 publication Critical patent/PE20212178A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PE2021001647A 2019-04-09 2020-04-07 Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria PE20212178A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019081900 2019-04-09
CN2019121598 2019-11-28
CN2020078225 2020-03-06
PCT/EP2020/059831 WO2020207991A1 (en) 2019-04-09 2020-04-07 Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
PE20212178A1 true PE20212178A1 (es) 2021-11-09

Family

ID=70228042

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001647A PE20212178A1 (es) 2019-04-09 2020-04-07 Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria

Country Status (19)

Country Link
US (1) US20220340597A1 (https=)
EP (1) EP3953356B1 (https=)
JP (1) JP7692838B2 (https=)
KR (1) KR20210149163A (https=)
CN (1) CN113710672B (https=)
AU (1) AU2020272467A1 (https=)
BR (1) BR112021020297A2 (https=)
CA (1) CA3135129A1 (https=)
CL (1) CL2021002621A1 (https=)
CO (1) CO2021013166A2 (https=)
CR (1) CR20210513A (https=)
IL (1) IL286870A (https=)
MA (1) MA55594A (https=)
MX (1) MX2021012223A (https=)
PE (1) PE20212178A1 (https=)
PH (1) PH12021552533A1 (https=)
SG (1) SG11202110401WA (https=)
TW (1) TW202104230A (https=)
WO (1) WO2020207991A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021084022A1 (en) * 2019-10-31 2021-05-06 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
CN114728959B (zh) * 2019-11-12 2024-11-12 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡嗪并[1,2-b]异喹啉化合物
US12503471B2 (en) 2019-11-19 2025-12-23 Hoffmann-La Roche Inc. Triazatricycle compounds for the treatment of autoimmune disease
CN114728976B (zh) 2019-11-19 2024-08-16 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
KR20220122637A (ko) 2019-11-28 2022-09-02 바이엘 악티엔게젤샤프트 면역 활성화를 위한 dgk알파 억제제로서의 치환된 아미노퀴놀론
WO2021110614A1 (en) * 2019-12-03 2021-06-10 F. Hoffmann-La Roche Ag HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
US20240317735A1 (en) * 2020-07-14 2024-09-26 Hoffmann-La Roche Inc. Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103562201B (zh) * 2011-01-12 2016-10-19 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
RS56747B1 (sr) 2012-09-14 2018-03-30 Hoffmann La Roche Pirazol derivati karboksamida kao taar modulatori za upotrebu u lečenju nekoliko poremećaja, kao što su depresija, dijabetes i parkinsonova bolest
CN105992766A (zh) * 2013-12-13 2016-10-05 武田药品工业株式会社 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物
CA3005766A1 (en) 2015-12-17 2017-06-22 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
EP3807271A1 (en) * 2018-06-13 2021-04-21 F. Hoffmann-La Roche AG Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease
JP2022501401A (ja) * 2018-09-27 2022-01-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 自己免疫疾患の治療のためのヘテロシクリル化合物

Also Published As

Publication number Publication date
PH12021552533A1 (en) 2022-06-20
CN113710672A (zh) 2021-11-26
AU2020272467A1 (en) 2021-10-14
EP3953356A1 (en) 2022-02-16
CO2021013166A2 (es) 2021-12-10
SG11202110401WA (en) 2021-10-28
CR20210513A (es) 2021-11-02
IL286870A (en) 2021-10-31
TW202104230A (zh) 2021-02-01
WO2020207991A1 (en) 2020-10-15
KR20210149163A (ko) 2021-12-08
BR112021020297A2 (pt) 2021-12-14
CA3135129A1 (en) 2020-10-15
CN113710672B (zh) 2025-01-03
EP3953356B1 (en) 2023-07-26
US20220340597A1 (en) 2022-10-27
MA55594A (fr) 2022-02-16
JP2022527588A (ja) 2022-06-02
JP7692838B2 (ja) 2025-06-16
CL2021002621A1 (es) 2022-05-13
MX2021012223A (es) 2021-11-03
EP3953356C0 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
PE20212178A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20170189A1 (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
CY1126367T1 (el) Παραγωγο βενζαζεπινης, μεθοδος παρασκευης, φαρμακευτικη συνθεση και χρηση αυτης
CL2019002032A1 (es) Procesos para preparar un inhibidor de jak1 (divisional de solicitud 1790-2018).
PE20190518A1 (es) Inhibidores de diacilglicerol aciltransferasa 2
CY1121231T1 (el) Παραγωγο τετραϋδροϊμιδαζο[1,5-d][1,4]οξαζεπινης
PE20210131A1 (es) COMPUESTOS TETRAHIDRO-1H-PIRAZINO[2,1-a]ISOINDOLILQUINOLINA PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES
PE20241068A1 (es) Moduladores de profarmacos de la via de estres integrada
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
PE20210163A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
PE20200936A1 (es) Dihidrooxadiazinonas
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
AR041184A1 (es) Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso
PE20160005A1 (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
AR071833A1 (es) Inhibidores de quinasas (limk2), composiciones que los comprenden y metodos para tratar o prevenir enfermedades
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20070805A1 (es) Imidazopirazinas como inhibidores de proteinquinasa
PE20220567A1 (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20200341A1 (es) Composiciones y compuestos terapeuticos y metodos para utilizarlos
PE20171348A1 (es) Compuestos de benzoxaborol 4-sustituidos y uso de los mismos